SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)

Keating et al., NCT04478019, SHIELD, NCT04478019, Jun 2022

PVP-I for COVID-19

14th treatment shown to reduce risk in February 2021, now with p = 0.0000000037 from 21 studies.

Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,600+ studies for 220+ treatments. c19early.org

Meta-analysis

245 participant povidone-iodine + chlorhexidine prophylaxis RCT with results not reported over 4 years after completion.

2 povidone-iodine RCTs have results missing long after expected1,2
The trials report a total of 295 patients, with 1 trial having actual enrollment of 245, and the other estimated.

Important missing comments or errors? Let us know.

Study covers chlorhexidine and povidone-iodine.

1. Khan et al., A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04634-2.biomedcentral.com, doi.org.

2. Keating et al., SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD), NCT04478019, clinicaltrials.gov/study/NCT04478019clinicaltrials.gov.

Keating et al., 30 Jun 2022, Randomized Controlled Trial, USA, this trial uses multiple treatments in the treatment arm (combined with chlorhexidine) - results of individual treatments may vary, trial NCT04478019 (history) (SHIELD). Contact: ns2@medicine.wisc.edu, dshirley@medicine.wisc.edu, jakeating@medicine.wisc.edu, SHIELD@medicine.wisc.edu, klhaight@medicine.wisc.edu, jperzynski@medicine.wisc.edu, mzimbric@medicine.wisc.edu.